05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines and pharmaceutical products for kidney disease
treatment and prevention; medicines and pharmaceutical
products for chronic kidney disease treatment and
prevention; medicines and pharmaceutical products for
pruritus treatment; medicines and pharmaceutical products
for pain treatment.
Vifor Fresenius Medical Care Renal Pharma, Ltd. (Suisse)
Inventeur(s)
Philipp, Erik
Müller, Hans-Martin
Kammerer, Michael
Abrégé
The invention relates to a new method of preparation of a polynuclear iron compound stabilized by carbohydrates and/or humic acid or forming a complex with carbohydrates and/or humic acid using a pressure-driven filtration process.
C07H 23/00 - Composés contenant du bore, du silicium ou un métal, p. ex. chélates ou vitamine B12
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
B01D 63/16 - Modules rotatifs, vibrants ou à mouvement alternatif
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Frison, Nicolas
Spichiger, Miriam
Ittel, Mélanie
Abrégé
The invention relates to particles of a mixture of iron(III)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide having a certain particle size distribution, a process for the manufacture thereof, the pharmaceutical composition comprising the same, in particular compressed tablets.
Vifor Fresenius Medical Care Renal Pharma Ltd. (Suisse)
Inventeur(s)
Chofflon, Laurent
Philipp, Erik
Abrégé
The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
Vifor Fresenius Medical Care Renal Pharma Ltd. (Suisse)
Inventeur(s)
Chofflon, Laurent
Philipp, Erik
Abrégé
The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA, LTD. (Suisse)
Inventeur(s)
Philipp, Erik
Müller, Hans-Martin
Kammerer, Michael
Abrégé
The invention relates to a new method of preparation of a polynuclear iron compound stabilized by carbohydrates and/or humic acid or forming a complex with carbohydrates and/or humic acid using a pressure-driven filtration process.
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
B01D 61/00 - Procédés de séparation utilisant des membranes semi-perméables, p. ex. dialyse, osmose ou ultrafiltrationAppareils, accessoires ou opérations auxiliaires, spécialement adaptés à cet effet
B01J 20/02 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique
B01J 20/06 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/24 - Composés macromoléculaires d'origine naturelle, p. ex. acides humiques ou leurs dérivés
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD. (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD. (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines and pharmaceutical preparations for the treatment and prevention of kidney diseases; medicines and pharmaceutical preparations for the treatment and prevention of chronic kidney diseases; medicines and pharmaceutical preparations for the treatment of pruritus; medicines and pharmaceutical preparations for the treatment of pain.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines and pharmaceutical preparations for the treatment and prevention of kidney diseases; medicines and pharmaceutical preparations for the treatment and prevention of chronic kidney diseases; medicines and pharmaceutical preparations for the treatment of pruritus; medicines and pharmaceutical preparations for the treatment of pain.
Vifor Fresenius Medical Care Renal Pharma Ltd (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Vifor Fresenius Medical Care Renal Pharma Ltd (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Vifor Fresenius Medical Care Renal Pharma Ltd (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Vifor Fresenius Medical Care Renal Pharma Ltd. (Suisse)
Inventeur(s)
Chofflon, Laurent
Philipp, Erik
Abrégé
The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
Vifor Fresenius Medical Care Renal Pharma Ltd. (Suisse)
Inventeur(s)
Chofflon, Laurent
Philipp, Erik
Abrégé
The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Robert Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
These compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
Vifor Fresenius Medical Care Renal Pharma Ltd (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Vifor Fresenius Medical Care Renal Pharma Ltd (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
09 - Appareils et instruments scientifiques et électriques
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific, checking (supervision), emergency (life-saving)
and teaching apparatus and instruments; software; database
and application integration software. Education; training; entertainment; sporting and cultural
activities. Scientific and technological services as well as research
and design services relating thereto; industrial analysis
and research services; design and development of computers
and software; provision of software platforms. Medical services; hygienic and beauty care for human
beings; advice provided by doctors and other medical
personnel; services provided by consultants relating to
pharmaceutical products; pharmaceutical consultancy.
09 - Appareils et instruments scientifiques et électriques
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific, checking (supervision), emergency (life-saving)
and teaching apparatus and instruments; software; database
and application integration software. Education; training; entertainment; sporting and cultural
activities. Scientific and technological services as well as research
and design services relating thereto; industrial analysis
and research services; design and development of computers
and software; provision of software platforms. Medical services; hygienic and beauty care for human
beings; advice provided by doctors and other medical
personnel; services provided by consultants relating to
pharmaceutical products; pharmaceutical consultancy.
Vifor Fresenius Medical Care Renal Pharma Ltd. (Suisse)
Inventeur(s)
Chofflon, Laurent
Philipp, Erik
Abrégé
The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
Vifor Fresenius Medical Care Renal Pharma Ltd. (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
A01N 33/26 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant des composés organiques de l'azote comportant des liaisons azote-azote, p. ex. des azides, composés diazoaminés, composés diazonium, dérivés de l'hydrazine
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Robert Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Robert Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Robert Zhiyong
Abrégé
The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, MMP-1 and MMP-3. Such diseases and conditions include cardiovascular inflammation, neurological inflammation, skeletal inflammation, muscular inflammation, gastrointestinal inflammation, ocular inflammation, otic inflammation, inflammation due to insect bites and inflammation due to wound healing; atherosclerosis, ischemia, restenosis and vasculitis; of asthma, Sjogren's syndrome, pulmonary inflammation, chronic airway inflammation and chronic obstructive pulmonary disease (COPD), allergy, psoriasis, psoriatic arthritis, eczema, scleroderma, atopic dermatitis and systemic lupus erythematosus, arthritis, synovitis, osteomyelitis, rheumatoid arthritis, osteoarthritis and ankylosing spondylitis; septicemia and septic shock, diabetes, glucose intolerance, insulin resistance and obesity, colitis, ulcerative colitis, Crohn's disease, IBD and IBS, and the inflammatory diseases and conditions due to tumor proliferation, tumor metastasis or transplantation rejection.
C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Robert Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frederique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Robert Zhiyong
Abrégé
The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as TNF-α, IL-β, IL-6, MMP-1 and MMP-3. Such diseases and conditions include cardiovascular inflammation, neurological inflammation, skeletal inflammation, muscular inflammation, gastrointestinal inflammation, ocular inflammation, otic inflammation, inflammation due to insect bites and inflammation due to wound healing; atherosclerosis, ischemia, restenosis and vasculitis; of asthma, Sjogren's syndrome, pulmonary inflammation, chronic airway inflammation and chronic obstructive pulmonary disease (COPD), allergy, psoriasis, psoriatic arthritis, eczema, scleroderma, atopic dermatitis and systemic lupus erythematosus, arthritis, synovitis, osteomyelitis, rheumatoid arthritis, osteoarthritis and ankylosing spondylitis; septicemia and septic shock, diabetes, glucose intolerance, insulin resistance and obesity, colitis, ulcerative colitis, Crohn's disease, IBD and IBS, and the inflammatory diseases and conditions due to tumor proliferation, tumor metastasis or transplantation rejection.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
wherein Xaa is a D-amino acid and G is selected from the following three groups:
The compounds are useful in the prophylaxis and treatment of pain, pruritis and inflammation associated with a variety of diseases and conditions.
Vifor Fresenius Medical Care Renal Pharma Ltd. (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frederique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
wherein Xaa is a D-amino acid and G is selected from the following three groups:
The compounds are useful in the prophylaxis and treatment of pain, pruritus and inflammation associated with a variety of diseases and conditions.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
wherein Xaa is a D-amino acid and G is selected from the following three groups:
The compounds are useful in the prophylaxis and treatment of pain, pruritis and inflammation associated with a variety of diseases and conditions.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. An exemplary synthetic tetrapeptide amide of the invention is D-Phe-D-Phe-D-Leu-(ε-Me) D-Lys-[4-Amidinohomopiperazine amide]:
Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (Suisse)
Inventeur(s)
Schteingart, Claudio D.
Menzaghi, Frédérique
Jiang, Guangcheng
Alexander, Roberta Vezza
Sueiras-Diaz, Javier
Spencer, Robert H.
Chalmers, Derek T.
Luo, Zhiyong
Abrégé
450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD. (Suisse)
Inventeur(s)
Weibel, Ludwig Daniel
Philipp, Erik
Abrégé
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to beswallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD. (Suisse)
Inventeur(s)
Chofflon, Laurent
Philipp, Erik
Abrégé
The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceuticalcomposition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA, LTD. (Suisse)
Inventeur(s)
Philipp, Erik
Muller, Hans-Martin
Kammerer, Michael
Abrégé
The invention relates to a new method of preparation of a polynuclear iron compound stabilized by carbohydrates and/or humic acid or forming a complex with carbohydrates and/or humic acid using a pressure-driven filtration process.
B01D 61/00 - Procédés de séparation utilisant des membranes semi-perméables, p. ex. dialyse, osmose ou ultrafiltrationAppareils, accessoires ou opérations auxiliaires, spécialement adaptés à cet effet
B01D 61/16 - Prétraitement du courant d'alimentation
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
B01J 20/02 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique
B01J 20/06 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/24 - Composés macromoléculaires d'origine naturelle, p. ex. acides humiques ou leurs dérivés
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
56.
PARTICLES OF A MIXTURE OF IRON(III)-OXYHYDROXIDE, SUCROSE AND ONE OR MORE STARCHES, PREFERABLY OF SUCROFERRIC OXYHYDROXIDE
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA, LTD. (Suisse)
Inventeur(s)
Frison, Nicolas
Spichiger, Miriam
Ittel, Melanie
Abrégé
The invention relates to particles of a mixture of iron(l I l)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide having a certain particle size distribution, a process for the manufacture thereof, the pharmaceutical composition comprising the same, in particular compressed tablets.
